Clinical trial
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia…
NCT00046488 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00046488 |
|---|---|
| Title | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) |
| Official title | A Phase I Multicenter, Dose-Escalation Study of IDEC-152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | IDEC-152 |
| Enrollment | 70 |
| Start date | Sep 1, 2002 |
| Primary completion | Apr 1, 2004 |
| Completion | Mar 1, 2010 |
| First posted | Oct 2, 2002 |
| Last update posted | Sep 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: